Insmed, Inc. (INSM)
124.03
-1.74
(-1.38%)
USD |
NASDAQ |
Aug 24, 16:00
124.03
0.00 (0.00%)
After-Hours: 20:00
Insmed EPS Diluted (Quarterly) : -0.0609 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0609 |
| March 31, 2026 | -0.7591 |
| December 31, 2025 | -1.538 |
| September 30, 2025 | -1.747 |
| June 30, 2025 | -1.699 |
| March 31, 2025 | -1.419 |
| December 31, 2024 | -1.316 |
| September 30, 2024 | -1.269 |
| June 30, 2024 | -1.943 |
| March 31, 2024 | -1.058 |
| December 31, 2023 | -1.285 |
| September 30, 2023 | -1.112 |
| June 30, 2023 | -1.780 |
| March 31, 2023 | -1.172 |
| December 31, 2022 | -1.207 |
| September 30, 2022 | -1.086 |
| June 30, 2022 | -0.7997 |
| March 31, 2022 | -0.7956 |
| December 31, 2021 | -0.9534 |
| September 30, 2021 | -0.9626 |
| June 30, 2021 | -1.071 |
| March 31, 2021 | -0.8894 |
| December 31, 2020 | -0.9992 |
| September 30, 2020 | -0.6265 |
| June 30, 2020 | -0.6401 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7392 |
| December 31, 2019 | -0.5923 |
| September 30, 2019 | -0.68 |
| June 30, 2019 | -0.8131 |
| March 31, 2019 | -0.9563 |
| December 31, 2018 | -1.188 |
| September 30, 2018 | -1.14 |
| June 30, 2018 | -1.00 |
| March 31, 2018 | -0.89 |
| December 31, 2017 | -0.85 |
| September 30, 2017 | -0.69 |
| June 30, 2017 | -0.72 |
| March 31, 2017 | -0.60 |
| December 31, 2016 | -1.10 |
| September 30, 2016 | -0.61 |
| June 30, 2016 | -0.59 |
| March 31, 2016 | -0.54 |
| December 31, 2015 | -0.51 |
| September 30, 2015 | -0.50 |
| June 30, 2015 | -0.47 |
| March 31, 2015 | -0.55 |
| December 31, 2014 | -0.36 |
| September 30, 2014 | -0.54 |
| June 30, 2014 | -0.59 |
| March 31, 2014 | -0.36 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| United Therapeutics Corp. | 7.271 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Biogen, Inc. | 0.6557 |
| Gilead Sciences, Inc. | -8.444 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -13.24M |
| Revenue (Quarterly) | 425.49M |
| Total Expenses (Quarterly) | 438.73M |
| Enterprise Value | 27.04B |
| Gross Profit Margin (Quarterly) | 83.71% |
| Profit Margin (Quarterly) | -3.11% |
| Earnings Yield | -3.31% |
| Normalized Earnings Yield | -3.228 |